Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005816 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
A Phase 1 study of Kidney Cancer, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00005816: Completed Phase 1 study of Kidney Cancer, sponsored by Duke University.
NCT00005816 is a Phase 1 study of Kidney Cancer that has completed, run by Duke University. The registered enrollment target is 15 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005816, a Phase 1 study of Kidney Cancer, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV kidney cancer.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL therapeutic autologous dendritic cells
Study Locations (1)
North Carolina
- Duke Comprehensive Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-02 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
What the finished NCT00005816 record still lists
NCT00005816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which conventional surgery is the first listed.
NCT00005816 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00005816 about?
NCT00005816 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV kidney cancer.
What is the current status of trial NCT00005816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2000-02. Estimated completion is 2002-08.
What conditions does trial NCT00005816 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00005816?
The interventions under investigation include: conventional surgery (PROCEDURE), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005816?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005816 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005816's enrollment target sits among peer trials
15 55th of 60 higher than 5 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study of VET3-TGI in Patients With Solid Tumors
RECRUITING · Phase 1
-
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia